Biomarker Validation in NPC1: Foundations for Clinical Trials and Regulatory Alignment

Area of Science:

• Biochemistry
• Genetics
• Neuroscience

Background:

• Niemann-Pick Type C1 (NPC1) disease is a rare, autosomal recessive neurovisceral lysosomal storage disorder.
• Caused by NPC1 gene mutations, it impairs cholesterol and lipid trafficking, leading to cellular accumulation.
• Clinical presentation is heterogeneous, with progressive neurological and systemic symptoms, often resulting in diagnostic delays.

Purpose of the Study:

• To review recent advances in understanding NPC1 disease.
• To highlight the development of diagnostic and prognostic biomarkers.
• To discuss the current therapeutic landscape and future directions for precision medicine.

Main Methods:

• Literature review of NPC1 disease mechanisms, clinical manifestations, and biomarker research.
• Analysis of current and emerging therapeutic strategies.
• Evaluation of biomarker candidates for NPC1 diagnosis and monitoring.

Main Results:

• Biomarker discovery is guided by cholesterol homeostasis dysregulation, neuroinflammation, and neuronal loss.
• Promising biomarkers include 24(S)-hydroxycholesterol, neurofilament light chain, bile acid derivatives, specific lipids, and oxysterols.
• Despite progress, NPC1 remains life-limiting with significant diagnostic and therapeutic gaps.

Conclusions:

• Earlier diagnosis and effective monitoring are crucial for managing NPC1 disease.
• Ongoing research and clinical trials are vital for biomarker qualification and developing disease-modifying treatments.
• An integrated approach combining molecular, biochemical, and clinical data is essential for advancing precision medicine in NPC1.